• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Research Briefing on 2-(2-phenylmethanesulfonyl-1H-1,3-benzodiazol-1-yl)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one (CAS: 886906-00-9)

The compound 2-(2-phenylmethanesulfonyl-1H-1,3-benzodiazol-1-yl)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one (CAS: 886906-00-9) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This briefing synthesizes the latest research findings on this compound, focusing on its synthesis, mechanism of action, and biological activity.

Recent studies have highlighted the compound's unique structural features, which combine a benzodiazole moiety with a tetrahydroquinoline scaffold. This hybrid structure is believed to contribute to its selective binding affinity for specific biological targets. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that the compound exhibits potent inhibitory activity against certain kinase enzymes, suggesting its potential as a lead candidate for the development of novel kinase inhibitors.

In terms of synthesis, researchers have developed an optimized multi-step route to produce 2-(2-phenylmethanesulfonyl-1H-1,3-benzodiazol-1-yl)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one with improved yield and purity. Key steps include the sulfonylation of the benzodiazole precursor and subsequent coupling with the tetrahydroquinoline derivative. The synthetic protocol has been successfully scaled up to gram quantities, facilitating further pharmacological evaluation.

Pharmacological profiling has revealed that the compound displays favorable drug-like properties, including moderate solubility and metabolic stability. In vitro assays have shown promising activity against several cancer cell lines, with IC50 values in the low micromolar range. Importantly, the compound appears to exhibit selectivity for cancer cells over normal cells, reducing the likelihood of off-target effects.

Mechanistic studies suggest that the compound's biological activity may be mediated through the modulation of key signaling pathways involved in cell proliferation and survival. Preliminary in vivo studies in xenograft models have demonstrated tumor growth inhibition, supporting further investigation of this compound as a potential anticancer agent. However, additional pharmacokinetic and toxicological studies are required to fully assess its therapeutic potential.

In conclusion, 2-(2-phenylmethanesulfonyl-1H-1,3-benzodiazol-1-yl)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one represents a promising scaffold for the development of novel therapeutic agents. Future research directions should focus on structure-activity relationship studies to optimize its pharmacological profile and elucidate its precise mechanism of action. The compound's unique chemical structure and biological activity make it a valuable subject for continued investigation in the field of medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)